For systems with multiple NVIDIA GPUs, NVFlash can update firmware for each GPU individually. Workstations and gaming systems with several graphics cards benefit from this.

Gamers and techies are always looking for improved computer hardware performance and customization. GPUs are integral to this pursuit, as they deliver high-quality graphics and smooth gameplay. Overclocking and third-party software are common ways to boost GPU performance, but NVIDIA card users have NiBiTor, the BIOS Editor. Changing the NVIDIA graphics card BIOS unlocks new flexibility and performance with this powerful software.

Kepler BIOS Tweaker lets users customize GPU performance. Fine-tuning your GPU is essential for gamers seeking more frames per second and professionals seeking continuous processing capability.

Одним из главных мифов является утверждение, что малоизвестные МФО не заслуживают доверия и представляют собой больший риск для заемщиков. Однако, многие из таких организаций работают в соответствии с требованиями украинского законодательства и предлагают свои услуги на вполне конкурентных основаниях.

Долгосрочный кредит с плохой кредитной историей традиционные банки часто считают рискованным, однако современные онлайн-сервисы зачастую готовы идти на такие шаги. Благодаря альтернативным методам оценки кредитоспособности, заемщики с неблагополучным кредитным прошлым тоже могут рассчитывать на одобрение заявок.

Получить кредитную карту и микрозайм гораздо проще, чем обычную банковскую ссуду. Новые положительные записи перекроют собой негативные моменты вашей кредитной истории. Если вам удалось получить кредит с плохой кредитной историей и просрочками в Украине 24/7, важно закрыть его в срок, тогда ваша КИ станет лучше.

CanceRNA

RNA Processing For Anti-Cancer Immunotherapy

Harnessing the power of RNA processing

CanceRNA aims to enhance the immunogenicity of “cold” cancers that lack genomic mutations and exploit abnormal transcripts to stimulate immune responses. This EU-sponsored consortium is at the forefront of transforming the landscape of cancer immunotherapy, promising a new era of treatment options for patients around the world

Harnessing RNA Processing For Cancer Immunotherapy: Introducing CanceRNA

The Hadassah Cancer Research Institute (HCRI) is proud to lead CANCERNA together with distinguished partners in the pharmaceutical and academic sectors as part of our ongoing commitment to drive transformative change in cancer research. This dynamic collaboration aims to develop and validate innovative RNA-based therapeutics targeting non-communicable diseases. Complementing our existing research portfolio, CANCERNA’s project undertakes an all-encompassing approach that includes in-vitro and in-vivo validation, bioinformatics, delivery, and safety assessments

The Promise of RNA-based Therapeutics

RNA-based therapies, particularly mRNA vaccines, have garnered global attention during the COVID-19 pandemic, saving millions of lives. However, their application in cancer therapy remains largely untested

CanceRNA's Vision and Strategy

CanceRNA’s three-year project encompasses a multitude of disciplines and activities to validate new and effective immunotherapy modalities for cancer treatment, both in-vitro and in-vivo. The goal is to expand on the successes of immunotherapy, such as its significant impacts on previously untreatable cancers like metastatic melanoma, and extend these benefits to a broader range of patients

An EU-sponsored Consortium

CanceRNA has received significant support from the European Union, securing an EIC Horizon Grant through the European Union’s Horizon-Health 2021 program. This support underscores the potential and significance of the consortium’s innovative research in revolutionizing cancer treatment

An International Collaboration

Comprised of twelve international groups, CanceRNA represents a robust collaborative effort. It includes pharmaceutical giant Merck KGaA, several leading European universities, and world-renowned research centers. These organizations and institutions are pooling their expertise to develop and validate novel RNA-based therapeutics for cancer treatment. This global collaboration testifies to the promise of RNA-based therapies and their potential to redefine the landscape of cancer treatment

In addition to its partnership with Merck, Hadassah University Hospital, and The Hadassah Cancer Research Institute (HCRI) in Jerusalem, CanceRNA is also collaborating with Jerusalem biotech start-up Immunyx Pharma, further solidifying its foothold in the cutting-edge field of RNA research and immunotherapy

For more information about CanceRNA and its innovative work, please visit www.cancerna.info.

Skip to content